Results 231 to 240 of about 1,539,304 (263)

Selective N‐Functionalization of Pyrazoles

European Journal of Organic Chemistry, EarlyView.
This review traces the evolution of regioselective N‐functionalization strategies for pyrazoles, a key class of nitrogen heterocycles widely used in medicinal chemistry. Due to rapid tautomerism, N‐functionalization often lacks selectivity, leading to poor and unpredictable regioisomeric outcomes.
Lucas Popek, Matthias Schrader, Christopher J. Teskey   +2 more
wiley   +1 more source

In vitro evidence for estrogen receptor activity of selected phase II isoflavone metabolites. [PDF]

Arch Toxicol
Grgic D, Bella-Velidou D, Dellafiora L, Soukup ST, Kulling SE, Varga E, Marko D.   +6 more
europepmc   +1 more source

The effect of antiseizure medications on the exposure to combined oral contraceptives: A systematic review and network meta‐analysis

Epileptic Disorders, EarlyView.
Abstract Objective Current recommendations for prescribing combined oral contraceptives (COCs) to people with epilepsy are often conflicting, particularly for weak inducers of cytochrome P450 3A4. We aimed to critically review the literature and compare the antiseizure medication (ASM)‐induced changes in exposure to COC components.
Hagar Cohen, Amnah Omar Mahajna, Tomer Ben‐Shushan, Ilan Matok, Sara Eyal   +4 more
wiley   +1 more source

Pharmacotherapeutic considerations of selective estrogen receptor modulators for vascular protection. [PDF]

Front Pharmacol
Al Banna J, Karam F, Hassanieh D, Khanafer YH, Seed Ahmed M, Sharara H, Eid AH.   +6 more
europepmc   +1 more source

Monthly or menstrual? A scoping review of catamenial epilepsy and non‐menstrual seizure rhythms

Epilepsia, EarlyView.
Abstract Objective Despite the reported high prevalence of catamenial epilepsy (CE), the condition remains poorly defined, with lack of consensus on what entails a menstrual‐related seizure exacerbation. Emerging evidence of multiday cycles of seizure activity, including about‐monthly cycles, present in both men and women, further confound the ...
Victoria Wong, Ewan S. Nurse, Ashley Reynolds, Mark J. Cook, Philippa J. Karoly   +4 more
wiley   +1 more source

Dose-dependent hormone actions at estrogen receptor enhancers specify distinct molecular and biological outcomes. [PDF]

Sci Adv
Kim HB, Nandu T, Kim YJ, Camacho CV, Kraus WL.   +4 more
europepmc   +1 more source

Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions. [PDF]

Front Oncol
Alasheev AY, Hamama R, Petersen EV, Maximov PY.   +3 more
europepmc   +1 more source

Real-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018-2024. [PDF]

Breast Cancer Res Treat
Meisel J, Pham T, Chen C, Kris A, Roose J.   +4 more
europepmc   +1 more source

Bisphenol BPAF and BPC are agonists for estrogen receptor ERα but antagonists for N-terminal domain-lacking ERα. [PDF]

PLoS One
Liu X, Shimohigashi M, Shimohigashi Y.
europepmc   +1 more source